Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis

Figure 7

(a) Incidence of hyperkalemia (≥5.5 mmol/l) in articles comparing eplerenone to placebo/active control. (b) Incidence of hyperkalemia (≥6.0 mmol/l) in articles comparing eplerenone to placebo/active control. The black diamond represents summary data with the center of the estimate pooled with the risk ratio, and the width covers the corresponding 95% CIs.

(a)

(b)